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BACKGROUD: There is a paucity of information on whether changes in metabolic syndrome (MetS) status affect the risk of new- 
onset atrial fibrillation (AF). We aimed to evaluate whether changes in MetS status and components of MetS affect AF risk 
using data from a nationwide observational cohort.
METHODS AND RESULTS: A total of 7 565 531 adults without prevalent AF (mean age, 47±14 years) who underwent 2 serial 
health examinations by the Korean National Health Insurance Cooperation were identified. The patients were categorized into 
4 groups according to the change in MetS status in serial evaluations, as follows: patients with persistent MetS (n=1 388 850), 
healthy patients newly diagnosed with MetS in the second evaluation (n=608 158), patients with MetS who were healthy in the 
second evaluation (n=798 555), and persistently healthy individuals (n=4 769 968). During a mean 7.9- year follow- up, incident 
AF was diagnosed in 139 305 (1.8%) patients. After multivariable adjustment, the AF risk was higher by 31% in the patients 
with persistent MetS , 26% in the patients with MetS who were healthy in the second evaluation, and 16% in the healthy 
patients newly diagnosed with MetS in the second evaluation compared with the persistently healthy individuals. Regardless 
of the MetS component type, the AF risk correlated with changes in the number of components. The risk of AF was strongly 
correlated with MetS status changes in the young and middle- age groups (20– 39 years and 40– 64 years, respectively) than 
in the elderly group (≥65 years).
CONCLUSIONS: Dynamic changes in MetS status and persistent MetS were associated with an increased risk of AF in a large- 
scale Asian population.
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The prevalence and incidence of atrial fibrillation (AF), the most common arrhythmia, are increasing worldwide, resulting in increased healthcare bur-
dens.1,2 Cardiovascular disease and its comorbidities, 
including metabolic syndrome (MetS), increase the risk 
of AF.3,4 MetS is a cluster of characteristics, including 
insulin resistance, central obesity, hypertension, and 
dyslipidemia, which themselves increase the risk of 
cardiovascular disease and adverse outcomes.5 The 
global prevalence of MetS has consistently increased, 
and in the Asia- Pacific region, nearly one fifth of the 
adult population has MetS.6 Therefore, active control 
of MetS or its components is expected to reduce the 
burden of AF and cardiovascular disease.7
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MetS components are potentially manageable with 
either lifestyle changes or medical treatment. Therefore, 
MetS component measurements may vary between 
different time points, and MetS status may change 
even during follow- up. Although previous studies fo-
cusing on the presence of MetS at baseline assess-
ment have evaluated the association between MetS 
and AF, the impact of changes in MetS status over 
time on AF development remains unknown.8,9 Herein, 
we aimed to evaluate whether changes in MetS status 
and each of its components affect AF risk based on a 
nationwide observational cohort.
METHODS
Data Source and Study Population
The data that support the findings of this study are avail-
able from the corresponding author upon reasonable 
request. The Korean government provides a universal 
health insurance service— the Korean National Health 
Insurance Service (NHIS)— to all Korean citizens. The 
NHIS database includes participants’ demographic 
data, diagnoses, and all claims of both inpatient and 
outpatient medical expenses, including prescrip-
tion records and procedures. The National Health 
Insurance Corporation also provides biennial general 
health examinations to all enrolled employer- provided 
participants of NHIS aged >20  years or locally pro-
vided participants of NHIS aged ≥40 years. This health 
examination includes physical examinations, a health 
status survey, and an assessment of blood and urine 
biochemical markers.10 Based on this database, we 
evaluated how AF risk related to changes in MetS sta-
tus (presence of MetS) and each MetS component in 2 
consecutive health examinations. We included patients 
who had undergone a baseline (the first during the 
study period) health examination from January 2008 
to December 2009 and those who had undergone a 
follow- up (the second during the study period) health 
examination from January 2010 to December 2011. All 
participants were followed up for AF occurrence from 
the time of the second health examination to December 
2017. Participants diagnosed with AF before the sec-
ond health examination were excluded. This study was 
exempt from review by the Seoul National University 
Hospital’s institutional review board (E- 1805- 074- 944) 
and adhered to the Declaration of Helsinki. Informed 
consent was waived because of the retrospective na-
ture of the study and anonymized data.
Definition of MetS and Other 
Comorbidities
MetS was defined according to the criteria of the 
American Heart Association/National Heart, Lung, and 
Blood Institute for Asian populations.11 MetS was diag-
nosed by the presence of any 3 of 5 components: (1) 
waist circumference ≥85 cm for women or ≥90 cm for 
men; (2) serum triglyceride ≥150 mg/dL or drug treat-
ment for elevated triglycerides; (3) serum high- density 
lipoprotein cholesterol <50 mg/dL in women or <40 mg/
dL in men; (4) systolic blood pressure (BP) ≥130 mm Hg 
or diastolic BP ≥85 mm Hg or drug treatment for elevated 
CLINICAL PERSPECTIVE
What Is New?
• Patients with persistent metabolic syndrome 
(MetS) had a higher atrial fibrillation (AF) risk, 
and those who were diagnosed with MetS at 
any time point showed a higher AF risk com-
pared with the consistently healthy individuals.
• Patients who persistently met the diagnostic cri-
teria for each component of MetS also showed 
higher AF risks.
• The AF risk became higher with an increas-
ing number of MetS components; AF risk was 
strongly correlated with changes in MetS status 
in the younger age group (<65 years).
What Are the Clinical Implications?
• This study is the first study to report the asso-
ciation between dynamic changes in MetS sta-
tus and the risk of new- onset AF and persistent 
MetS was associated with an increased risk of 
AF.
• Patients who were diagnosed with MetS at any 
time point showed significantly higher risks for 
new- onset AF than those without MetS follow-
ing serial health examination.
• Intensive care and management of metabolic 
abnormalities might improve the AF risk, espe-
cially in younger patients.
Nonstandard Abbreviations and Acronyms
HH patients who were metabolically healthy 
at both examinations
HM patients who were metabolically healthy 
at the first examination but were newly 
diagnosed with metabolic syndrome at 
the second examination
MetS metabolic syndrome
MH patients with metabolic syndrome at the 
first examination but became 
metabolically healthy at the second 
examination
MM patients who met metabolic syndrome 
criteria at both health examinations
NHIS National Health Insurance Service
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BP; and (5) fasting plasma glucose ≥100 mg/dL or drug 
treatment for elevated blood glucose. Obesity was 
defined according to the World Health Organization’s 
Western Pacific Region Office definition of obesity for 
Asians: obese group (body mass index [BMI] ≥25 kg/m2) 
and nonobese group (BMI <25 kg/m2).12
To investigate the impact of MetS status changes, 
the study population was stratified into 4 groups ac-
cording to the presence of MetS on the first and sec-
ond health examination: (1) the MM group included 
patients who met MetS criteria at both health exam-
inations; (2) the HM group included those who were 
metabolically healthy at the first examination but was 
newly diagnosed with MetS at the second examina-
tion; (3) the MH group included those who had MetS at 
the first examination but became metabolically healthy 
at the second examination; and (4) the HH group in-
cluded those who were metabolically healthy at both 
examinations. To define metabolically healthy, ≤2 MetS 
component criteria were selected, as in previous MetS 
studies.13,14 The study population stratified flow is sum-
marized in Figure 1 and Figure S1.
Baseline comorbidities of patients were analyzed 
based on the existing corresponding International 
Classification of Diseases, Tenth Revision, Clinical 
Modification (ICD- 10- CM) codes in the claims data, 
and these were validated in our previous reports.4,15 
Table S1 describes the detailed definitions of baseline 
comorbidities and ICD- 10 codes.
Study End Point
The primary end point was newly diagnosed AF (ICD- 
10 codes I480– I484 and I489) after the second health 
examination during the follow- up period. To ensure di-
agnostic accuracy, AF was defined when the diagnosis 
was confirmed more than twice in the outpatient clinic 
or confirmed on hospital discharge.4,16
Statistical Analysis
Patient data are presented as mean±SD for continu-
ous variables and as numbers and percentages for cat-
egorical variables. To determine the differences among 
groups, we used Student t test for continuous values and 
chi- square test for categorical variables. The incidence 
rate of AF in each group was estimated by 1000 patient- 
years. The multivariable Cox proportional hazards model 
was used to identify comorbidities associated with the 
development of AF. Multivariable adjustments were made 
for sex, age, smoking status, alcohol intake, exercise sta-
tus, and BMI. The proportional hazards assumption was 
evaluated by Schoenfeld residuals test with the logarithm 
of the cumulative hazards function based on Kaplan– 
Meier estimates for the categories of stratified MetS 
status change. To evaluate the effect of age on AF risk, 
we performed subgroup analysis with the stratified age 
group. Two- sided P values <0.05 were considered statis-
tically significant. All statistical analyses were performed 
using SAS version 9.2 software (SAS Institute Inc).
RESULTS
Baseline Characteristics of the Study 
Population
A total of 7 565 531 participants were included in this 
study (mean age, 47.2±13.7 years; men 55.6%). During 
the mean follow- up of 7.9 years (a total of 59 677 004 
Figure 1. Study population stratified flow according to the change of metabolic syndrome status 
and those of metabolic components.
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patient- years follow- up duration), 135 600 (1.79%) pa-
tients were newly diagnosed with AF (2.27 per 1000 
patient- years). Study participants were classified into 4 
groups according to change of MetS status as follows: 
MM, 1  388  850 (18.4%); MH, 798  555 (10.5%); HM, 
608 158 (8.0%); and HH, 4 769 968 (63.1%). The base-
line characteristics of the study population are sum-
marized in Table.
Table 1. Baseline Characteristics by Variation of MetS Change Status
Total HH HM MH MM
Patients 7 565 531 (100.0) 4 769 968 (63.1) 608 158 (8.0) 798 555 (10.6) 1 388 850 (18.4)
Age, y 47.2±13.7 43.4±12.78 51.3±13.0 50.6±13.0 56.2±12.3
Men 4 209 273 (55.6) 2 629 853 (55.1) 371 390 (61.1) 482 584 (60.4) 725 446 (52.2)
BMI, kg/m2 23.7±3.2 22.7±2.7 25.1±2.9 24.8±2.8 26.1±3.1
MetS components, n 1.56±1.37 0.81±0.77 1.50±0.65 3.26±0.50 3.66±0.71
Waist circumference, cm 80.6±9.0 77.5±8.1 83.0±7.6 85.2±7.8 87.4±8.1
Systolic BP, mm Hg 122.4±14.6 118.4±13.3 124.9±13.8 129.6±13.5 131.0±14.5
Diastolic BP, mm Hg 76.3±9.8 74.2±9.2 77.8±9.3 80.5±9.5 80.4±9.9
FBG, mg/dL 96.7 ± 21.6 91.4±14.2 104.2±23.0 97.1±21.3 111.6±31.8
Total cholesterol, mg/dL 195.4±36.2 189.9±32.9 204.0±38.1 205.4±36.3 204.4±41.9
LDL- C, mg/dL 114.1±33.2 111.2±30.1 118.5±36.1 123.4±34.2 116.7±39.3
HDL- C, mg/dL 55.2±17.3 57.9±16.5 49.3±16.7 53.8±18.6 49.3±17.5
Triglycerides, mg/dL 113.2 (113.2– 113.3) 93.2 (93.1– 93.2) 164.5 (164.3– 164.7) 127.7 (127.5– 127.8) 173.3 (173.1– 173.4)
Diabetes mellitus 618 456 (8.2) 102 973 (2.2) 68 489 (11.3) 58 479 (7.3) 388 515 (28.0)
Hypertension 1 896 460 (25.1) 528 448 (11.1) 245 103 (40.3) 231 287 (29.0) 891 622 (64.2)
Liver cirrhosis 19 064 (0.3) 10 939 (0.2) 1877 (0.3) 2212 (0.3) 4036 (0.3)
Stroke/TIA/TE 116 965 (1.6) 27 683 (0.6) 12 512 (2.1) 14 484 (1.8) 62 285 (4.5)
Ischemic heart disease 226 342 (3.0) 44 066 (0.9) 23 662 (3.9) 22 855 (2.9) 135 759 (9.8)
Peripheral artery disease 182 224 (2.4) 51 894 (1.1) 20 323 (3.3) 23 377 (2.9) 86 630 (6.2)
Heart failure 35 943 (0.5) 9107 (0.2) 4105 (0.7) 4167 (0.5) 18 564 (1.3)
Smoking
Nonsmoker 4 516 917 (59.7) 2 888 657 (60.6) 337 437 (55.5) 441 155 (55.2) 849 668 (61.2)
Ex- smoker 1 157 971 (15.3) 680 901 (14.3) 109 982 (18.1) 131 959 (16.5) 235 129 (16.9)
Current smoker 1 890 643 (25.0) 1 200 410 (25.2) 160 739 (26.4) 225 441 (28.2) 304 053 (21.9)
Alcohol use*
Absent 3 865 929 (51.1) 2 335 904 (49.0) 311 437 (51.2) 403 649 (50.6) 814 939 (58.7)
Consumption 3 204 150 (42.4) 2 159 791 (45.3) 246 486 (40.5) 329 585 (41.3) 468 288 (33.7)
Heavy drinker 495 452 (6.6) 274 273 (5.8) 50 235 (8.3) 65 321 (8.18) 105 623 (7.6)
Physical activity†
Low activity 3 521 194 (46.5) 2 166 259 (45.4) 289 522 (47.6) 371 181 (46.5) 694 232 (50.0)
Mid and high activity 4 044 337 (53.5) 2 603 709 (54.6) 318 636 (52.4) 427 374 (53.5) 694 618 (50.0)
Income
Over 20 percentiles 5 876 144 (77.7) 3 707 744 (77.7) 473 497 (77.9) 618 593 (77.5) 1 076 310 (77.5)
Under 20 percentiles 1 689 387 (22.3) 1 062 224 (22.3) 134 661 (22.1) 179 962 (22.5) 312 540 (22.5)
Obesity (BMI ≥25 kg/m2) 2 425 708 (32.1) 890 128 (18.7) 301 599 (49.6) 358 825 (44.9) 875 156 (63.0)
Patients with AF 135 600 (1.8) 55 975 (1.2) 14 090 (2.3) 18 969 (2.4) 46 566 (3.4)
AF incidence (1000 
patient- y)
2.3 1.5 2.9 3.0 4.3
Follow- up duration, y 7.9±0.9 7.9±0.8 7.9±1.0 7.9±1.0 7.8±1.1
Values are expressed as mean±SD or number (percentage). AF indicates atrial fibrillation; BMI, body mass index; BP, blood pressure; FBG, fasting blood 
glucose; HDL- C, high- density lipoprotein cholesterol; HH, patients who were metabolically healthy at both examinations; HM, patients who were metabolically 
healthy at the first examination but were newly diagnosed with metabolic syndrome at the second examination; LDL- C, low- density lipoprotein cholesterol; 
MetS, metabolic syndrome; MH, patients with metabolic syndrome at the first examination but became metabolically healthy at the second examination; MM, 
patients who met metabolic syndrome criteria at both health examinations, TE, thromboembolism; and TIA, transient ischemic attack.
*Heavy drinker is defined as an invididual with an average daily alcohol intake of ≥30 g (3 pints of beer).
†Mid and high physical activity are defined as during the past week, moderate intensity exercise >5 times per week for >30 minutes or vigorous intensity 
exercise for >3 times per week for >20 minutes.
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Generally, the MM group had higher risk profiles 
for AF development than other groups. MM was the 
oldest group (mean age, 56.2±12.3 years) and HH the 
youngest (mean age, 43.4±12.8 years). For each MetS 
component, the mean waist circumference, systolic 
BP, fasting blood glucose, and triglyceride level were 
highest in the MM group and lowest in the HH group. 
The mean high- density lipoprotein level was highest in 
the HH group and lowest in the MM group. The MM 
group showed the highest mean BMI (26.1±3.1 kg/m2) 
and the highest proportion of obese patients (63.0%, 
875 156 patients).
Association Between Changes in MetS 
Status and New- Onset AF
The average time from the end of the second health 
examination to the onset of AF was 3.3±1.8  years 
for all patients with AF in this study population. The 
crude incidence rates of AF for the HH, HM, MH, and 
MM groups were 1.48, 2.94, 3.02, and 4.30 per 1000 
patient- years, respectively. Patients who were diag-
nosed with MetS during inclusion periods (HM, MH, 
and MM groups) showed a >2- fold higher incidence of 
AF than the HH group. After multivariable adjustment, 
the AF risk was higher by 31% in the MM group (hazard 
ratio [HR], 1.308; 95% CI, 1.290– 1.327), 26% in the MH 
group (HR, 1.259; 95% CI, 1.238– 1.280), and 16% in 
the HM group (HR, 1.155; 95% CI, 1.134– 1.178) com-
pared with the HH group, respectively (Figure 2). Each 
component of MetS was similar to the main results. 
The patients who persistently met the diagnostic cri-
teria for each component of MetS (UU group) showed 
the highest AF risk compared with the HH, HU, and UH 
groups for each MetS component (Table S2). Among 
those who received the third health examination during 
the follow- up period (56.9% of the total study popula-
tion), patients with persistent MetS showed the highest 
risk of AF (HR, 1.27; 95% CI, 1.24– 1.31). Also, those 
who met the diagnostic criteria for MetS at any time 
point showed a higher risk of AF compared with those 
who were consistently healthy (Table S3).
Association Between Changes in the 
Number of MetS Components and AF 
Risk
We analyzed the impact of changes in the number 
of MetS components on AF development. Figure 3 
shows patient distributions according to changes in 
MetS component number. AF risk showed a gradual 
response to the change in MetS component num-
ber. In patients who had zero or 1 MetS component 
at the baseline health examination, the AF risk grad-
ually increased with the number of new MetS com-
ponents at the second examination. When patients 
had 2, 3, and 4 MetS components at the second ex-
amination, the AF risk was higher by 16%, 32%, and 
47%, respectively, compared with those maintaining 
≤1 components (HR, 1.164 [95% CI, 1.138– 1.192]; 
Figure 2. The risk of atrial fibrillation (AF) according to the changes in metabolic syndrome (MetS) status.
A, Proportion of each study group according to MetS status change. B, Risk of AF according to MetS status changes. HR indicates 
hazard ratio. *The definition of each divided group is as follows: HH, patients who were metabolically healthy at both examinations; 
HM, patients who were metabolically healthy at the first examination but were newly diagnosed with MetS at the second examination; 
MH, patients with MetS at the first examination but became metabolically healthy at the second examination; and MM, patients who 
met MetS criteria at both health examinations. †Multivariable models adjusted for age, sex, alcohol consumption, smoking status, 
physical activity, and body mass index.
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HR, 1.316 [95% CI, 1.275– 1.357]; and HR, 1.465 
[95% CI, 1.397– 1.536], respectively) (Figure 3A). 
Regardless of the number of MetS components in 
the first examination, the AF risk became higher as 
the number of components increased, and the AF 
risk became lower as the number of components de-
creased compared with those who maintained their 
MetS component number(s) in the follow- up exami-
nation. Of patients who had 2 MetS components at 
the first examination, those whose component num-
ber decreased to 1 at the second examination had 
a lower AF risk than those who maintained 2 com-
ponents (Figure 3B). Of the patients with ≥3 MetS 
components at the first examination, those who had 
fewer MetS components at the second examination 
showed a lower AF risk than those who maintained 
or had increased number of components (Figure 3C 
and 3D).
In patients who had ≤1 MetS components at the 
second examination, the AF risk gradually increased 
according to the number of MetS components at 
baseline (Figure  4). When patients had 2, 3, and 4 
MetS components at baseline, the AF risk increased 
by 11%, 19%, and 29%, respectively, compared with 
those maintaining ≤1 components (HR, 1.108 [95% CI, 
1.081– 1.136]; HR, 1.193 [95% CI, 1.151– 1.236]; and HR, 
1.285 [95% CI, 1.209– 1.367], respectively) (Figure 4A). 
Among patients with ≥3 MetS components at the sec-
ond examination, the AF risks were similar, regard-
less of the number of MetS components at baseline 
(Figure 4C and 4D). The incidence rates and HRs of 
AF among patients stratified by the number of MetS 
components are shown in Table S4.
Subgroup Analysis
We performed stratified analyses of AF risk associ-
ated with changes in MetS status and components 
according to age (Figure 5). We divided the patients 
into 3 groups: young (20– 39 years), middle age (40– 
64 years), and old age (≥65 years). The AF risk was 
strongly correlated with changes in MetS status in the 
young and middle age groups, whereas the AF risk 
in the old age group was not. With respect to MetS 
components, the AF risk closely correlated with the 
change in MetS components in the young and middle 
age groups, while the AF risk in the old age group was 
not. Changes in the BP component conferred similar 
AF risks for all age groups. The incidence rate and 
AF risk in each subgroup by age are summarized in 
Table S5.
Figure 3. Study population distribution and the risk of atrial fibrillation (AF) according to changes in metabolic syndrome 
(MetS) components based on the number of components in the first health examination.
A, Risk of AF according to changes in MetS components of patients who had 0 or 1 component in the first health examination. B, 
Risk of AF according to changes in MetS components of patients who had 2 components in the first health examination. C, Risk of AF 
according to changes in MetS components of patients who had 3 components in the first health examination. D, Risk of AF according 
to changes in MetS components of patients who had ≥4 components in the first health examination. Ref, reference; NC, no change 
in the number of MetS components; Inc, increase in the number of MetS components; and Dec, decrease in the number of MetS 
components. *Multivariable models adjusted for age, sex, alcohol consumption, smoking status, physical activity, and body mass 
index.
J Am Heart Assoc. 2021;10:e020901. DOI: 10.1161/JAHA.121.020901 7
Lee et al Metabolic Status Changes and Risk of AF
DISCUSSION
In this study, our principal findings are as follows: (1) 
patients with persistent MetS had the highest AF risk, 
and those who met the diagnostic criteria for MetS at 
any time point showed a higher AF risk compared with 
the consistently healthy population; (2) patients who 
persistently met the diagnostic criteria for each compo-
nent of MetS, which are also independent risk factors 
for AF, showed higher AF risks; (3) regardless of MetS 
components type, the AF risk became higher with in-
creasing number of MetS components, and AF risk 
became lower with decreasing number of MetS com-
ponents; and (4) AF risk was more strongly correlated 
with changes in MetS status in the young and middle 
age groups than in the old age group (≥65 years).
To the best of our knowledge, this is the first study 
to report the association between dynamic changes 
in MetS status and the risk of new- onset AF and how 
persistent MetS was associated with an increased risk 
of AF using in a nationwide observational cohort.
Change in MetS Status and AF Risk
MetS involves risk factors associated with cardiovas-
cular disease and cardiac arrhythmia, such as AF. 
The relationship between MetS and increased risks 
of new- onset AF has been previously reported.3,7,17– 19 
Moreover, each MetS component is associated with 
increased risks of AF.17,20 Our study results corrobo-
rate the findings of previous studies that patients with 
MetS show a higher AF risk and changes in MetS sta-
tus during follow- up may affect the AF risk. In addition, 
recovery of MetS status to metabolically healthy status 
is associated with a risk reduction for AF. The group 
that improved from MetS status to healthy status (MH 
group: HR, 1.308; 95% CI, 1.29– 1.327) had ≈5% lower 
risk than those with persistent MetS (MM group: HR, 
1.259; 95% CI, 1.28– 1.28). Also, if the MH group per-
sistently maintained a healthy status (HR, 1.109; 95% 
CI, 1.06– 1.159), they had ≈16% lower risk than the 
group with consistently remaining MetS (HR, 1.273; 
95% CI, 1.238– 1.309). Moreover, there was associated 
AF risk reduction when each of the MetS elements, 
such as waist circumference, high blood pressure, and 
high fasting glucose, were restored to healthy status 
(Table S2 and S3).
Several studies have reported on the increased 
risks of cardiovascular disease and mortality caused 
by changes or fluctuations in MetS components, BP, 
fasting glucose levels, and obesity during follow- up.21,22 
Fluctuations in BP and cholesterol levels and higher 
longitudinal fluctuations in fasting blood glucose lev-
els, regardless of the presence of diabetes mellitus, 
during follow- up are associated with increased risks 
Figure 4. Study population distribution and the risk of atrial fibrillation (AF) according to the changes in metabolic syndrome 
(MetS) components based on the number of components in the second health examination.
A, Risk of AF according to changes in MetS components of patients who had 0 or 1 component in the second health examination. B, 
Risk of AF according to changes in MetS components of patients who had 2 components in the second health examination. C, Risk 
of AF according to changes in MetS components of patients who had 3 components in the second health examination D, Risk of AF 
according to changes in MetS components of patients who had ≥4 components in the second health examination. Ref, reference; 
NC, no change in the number of MetS components; Inc, increase in the number of MetS components; Dec, decrease in the number 
of MetS components. *Multivariable models adjusted for age, sex, alcohol consumption, smoking status, physical activity, and body 
mass index.
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of cardiovascular disease and mortality.23,24 A recent 
study reported that BMI changes during follow- up 
were associated with increased risks of cardiovascular 
events, including new- onset AF.25 Expectedly, patients 
in our study with persistent MetS had the highest risk 
of developing AF. However, we show for the first time 
that patients who were diagnosed MetS at any time 
point showed significantly higher risks for new- onset 
AF than those without MetS following serial health 
examination.
Changes in the Number of MetS 
Components and AF Risk
In previous studies, each MetS component was as-
sociated with increased risks of AF.3,7,8 Studies on the 
relationships between changes in the number of MetS 
components and AF risk are limited. As the number 
of MetS components increase, the risk of AF risk is 
also increases, in proportion with an increasing num-
ber of MetS components.7,19 Our results support previ-
ous studies showing that AF risk becomes higher with 
an increased number of MetS components in Asian 
populations, while a decrease in the number of MetS 
components (thus, an improvement in MetS status) 
correlates with a lower AF risk. Importantly, the extent 
of risk reduction was affected by the number of MetS 
components involved before the improvement.
Considering that MetS includes several metabol-
ically related cardiovascular risk factors, it was pre-
viously unclear how they affect each other when ≥2 
components are involved. In the present study, we 
found that when any MetS component improved 
to within the normal range, the AF risk decreased. 
The degree of risk decrease may be related to the 
number of MetS components involved during the 
baseline examination. Our findings suggest a “neg-
ative legacy effect” in that the more initially present 
metabolic aberrant- causing components, the longer 
the detrimental effect persists, despite careful MetS 
component control over time. Negative legacy effects 
on metabolic abnormalities were reported for obese 
patients with type 2 diabetes mellitus, in whom car-
diovascular disease risk persists after weight loss.26 
Figure 5. The risk of atrial fibrillation (AF) according to the changes in metabolic syndrome (MetS) status by age groups.
A, Risk of AF according to MetS status changes by age groups. B, Risk of AF according to waist circumference status changes by 
age groups. C, Risk of AF according to blood pressure (BP) status changes by age groups. D, Risk of AF according to fasting glucose 
status changes by age groups. E, Risk of AF according to triglyceride status changes by age groups. F, Risk of AF according to high- 
density lipoprotein cholesterol (HDL- C) status changes by age groups. †The definition of each divided group (HH, HM, MH, MM) same 
as Figure 2. ‡Subjects stratified into four groups according to the change of relevant component of metabolic syndrome as follows: 
UU, metabolically unhealthy of relevant component in both checkups; UH, metabolically unhealthy of relevant component in the first 
exam but changed to healthy in the second checkup; HU, metabolically healthy of relevant component in the first exam but changed 
to unhealthy in the second checkup; and HH, metabolically healthy of relevant component in both checkups. AF, atrial fibrillation; BP, 
blood pressure; HDL, high- density lipoprotein cholesterol; MetS, metabolic syndrome; TG, triglyceride.
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However, this does not indicate that the benefits of 
controlling metabolic abnormalities are completely 
eradicated. In our study, regardless of the number and 
MetS component type diagnosed in the first health 
examination, the AF risk generally became lower as 
the number of MetS components decreased. This 
suggests that not only waist circumference but any 
MetS component could be a modifiable or manage-
able risk factor,8 and any effort to normalize meta-
bolic abnormalities could reduce AF risk.
Age, MetS Components, and AF Risk
Age is an important independent risk factor for both 
MetS and AF.27 In this study, we stratified the study 
population into different age groups and found that 
changes in MetS status and each MetS component 
affected AF risk in young and middle age groups more 
dramatically than in the old age group.28 AF risk asso-
ciated with a change of MetS status showed that the 
MM group had a 57% higher risk than the HH group 
in the young age group, but in the old age group, the 
AF risk in the MM group was only 15% higher than 
in the HH group. Most MetS components were also 
more closely correlated with AF risk according to sta-
tus changes of each MetS component in the young 
age compared with the old age group.
As in previous studies, the incidence and risk of 
AF markedly increased with aging, and younger pa-
tients had a relatively lower risk of AF.27 Our results 
suggest that changes in MetS status and each com-
ponent of MetS had a greater impact on the AF risk 
in the young age group compared with the older age 
group. AF developing at a young age often presents 
with typical symptoms such as palpitations or chest 
pain and has an impact on quality of life. In addition, 
uncontrolled new- onset AF would change to chronic 
AF, eventually increasing the risk of heart failure and 
stroke.29 Therefore, meticulous attention to, and pro-
active management of, metabolic abnormalities may 
lower the risk of AF, especially in the young population.
In some previous studies, a metabolically unhealthy 
status had an accentuated impact on AF risk at a 
young age. Obese or overweight women of a young 
age group (<60 years) were more likely to be associ-
ated with AF risk than elderly populations,30 and the re-
lationship between type 2 diabetes mellitus and AF risk 
was also stronger in younger people than in the old.31 
Recently, attention to multiple genetic loci and genetic 
variations associated with MetS and its complication 
at a young age is also increasing. However, most pre-
vious studies report that MetS and its complications 
are greatly influenced by lifestyle and environmental 
factors.32,33 Therefore, better care and management 
of metabolic abnormalities might improve the AF risk, 
especially in younger patients.
Study Limitations
Our study had several limitations. First, the diagnoses 
of new- onset AF and other comorbidities were based 
on the claims database of the NHIS, which relies on the 
physician’s diagnosis. Therefore, there is a possibility of 
AF misdiagnosis and an overestimation of outcomes or 
other comorbidities. To alleviate this bias, we used the 
validated definition of AF and comorbidities based on 
the NHIS cohort from our previous study.4,16 Second, 
this cohort was composed of a homogenous Asian 
race; therefore, the study’s findings are not representa-
tive of the global population and should be evaluated in 
other ethnicities. Third, we could not calculate the du-
ration of MetS. Earlier health examination data before 
2008 were not available in the NHIS database, there-
fore the effect of MetS duration could not be analyzed. 
Fourth, although we tried to adjust for all available vari-
ables using multivariable analysis, unmeasurable con-
founders such as inflammatory markers or dietary habits 
could still remain. Finally, this is an observational cohort 
study based on retrospectively collected data; therefore, 
we describe associations rather than a causal relation-
ship. In addition, the degree of influence between each 
MetS component could not be determined by simplisti-
cally comparing values of HRs in the current study. This 
would require substantially more comprehensive analy-
ses taking into consideration more variables.
CONCLUSIONS
In our large Asian cohort, persistent MetS was as-
sociated with increased AF risks, and patients diag-
nosed with MetS at any time during follow- up showed 
a higher AF risk compared with a consistently meta-
bolically healthy population. Moreover, AF risk became 
higher as the number of MetS components increased 
and became lower as the number of MetS compo-
nents decreased. Changes in MetS status and each 
MetS component were strongly correlated with AF risk, 
especially in the young and middle- aged populations.
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Supplemental Material 
Table S1. Definitions of comorbidities.  
Diagnosis ICD-10-CM code and definition 
Hypertension* 
I10-I13, I15; and minimum 1 prescription of anti-hypertensive drug (thiazide, loop diuretics, aldosterone antagonist, alpha-
/beta-blocker, calcium-channel blocker, angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker). 
Diabetes mellitus† 
E11-E14; and minimum 1 prescription of anti-diabetic drugs (sulfonylureas, metformin, meglitinides, thiazolidinediones, 
dipeptidyl peptidase-4 inhibitors, α-glucosidase inhibitors, and insulin). 
Liver cirrhosis K74, K70.3, K70.4  
Stroke I63, I64 
Transient ischemic attack G458, G459 
Thromboembolism  I74 
Myocardial infarction† I21-22 
Congestive heart failure† I50 
Peripheral arterial disease * I70, I73 
* ≥ 1 diagnosis during hospitalization, or ≥ 2 diagnoses at outpatient clinic, in the previous 1 year 
†≥ 1 diagnosis during hospitalization or at outpatient clinic, in the previous 1 year 
ICD-10-CM, the International Classification of Disease, Tenth Revision, Clinical Modification;  
  
Table S2. AF risk according to each of metabolic syndrome component variation.  
    Total 
  




HR (95% CI)* 
    Model1 Model2 
Metabolic syndrome†   
 HH 4,769,968 55,975 1.481 1(reference) 1(reference) 
 HM 608,158 14,090 2.944 1.237 (1.214-1.26) 1.155 (1.134-1.178) 
 MH 798,555 18,969 3.022 1.335 (1.313-1.357) 1.259 (1.238-1.28) 
  MM 1,388,850 46,566 4.300 1.454 (1.435-1.473) 1.308 (1.29-1.327) 
Increased waist circumference‡    
 HH 5,557,418 79,689 1.814 1(reference) 1(reference) 
 HU 484,393 12,837 3.380 1.266 (1.242-1.29) 1.175 (1.151-1.198) 
 UH 559,475 12,830 2.916 1.247 (1.224-1.27) 1.171 (1.148-1.194) 
 UU 964,245 30,244 4.009 1.485 (1.465-1.505) 1.312 (1.289-1.335) 
High blood pressure‡    
 HH 3,322,639 29,858 1.134 1(reference) 1(reference) 
 HU 823,877 13,006 1.995 1.234 (1.209-1.26) 1.183 (1.158-1.208) 
 UH 963,237 15,906 2.085 1.264 (1.24-1.289) 1.214 (1.191-1.238) 
 UU 2,455,778 76,830 4.003 1.581 (1.559-1.604) 1.462 (1.441-1.484) 
High fasting glucose‡    
 HH 4,259,720 57,708 1.711 1(reference) 1(reference) 
 HU 865,970 16,787 2.456 1.112 (1.093-1.131) 1.078 (1.06-1.097) 
 UH 993,115 19,877 2.539 1.136 (1.118-1.155) 1.098 (1.08-1.115) 
 UU 1,446,726 41,228 3.656 1.197 (1.182-1.213) 1.122 (1.107-1.137) 
High triglyceride‡    
 HH 3,968,673 55,786 1.780 1(reference) 1(reference) 
 HU 783,301 15,546 2.515 1.05 (1.031-1.069) 0.987 (0.97-1.005) 
 UH 947,270 19,548 2.615 1.162 (1.14-1.181) 1.107 (1.089-1.125) 
 UU 1,866,287 44,720 3.046 1.147 (1.133-1.162) 1.047 (1.033-1.06)  
Low HDL-C‡    
 HH 4,621,611 62,431 1.707 1(reference) 1(reference) 
 HU 737,844 14,542 2.493 1.125 (1.105-1.146) 1.087 (1.067-1.107) 
 UH 879,956 20,889 3.028 1.29 (1.27-1.311) 1.242 (1.223-1.262) 
  UU 1,326,120 37,738 3.637 1.284 (1.267-1.302) 1.212 (1.196-1.229) 
Obesity       
 HH 4,710,947 73,095 1.966 1(reference) 1(reference) 
 HU 356,409 8,444 3.017 1.209 (1.182-1.236) 1.207 (1.18-1.235) 
 UH 428,876 7,654 2.256 1.164 (1.137-1.192) 1.162 (1.135-1.19) 
  UU 2,069,299 46,407 2.847 1.328 (1.313-1.344) 1.324 (1.309-1.34) 
* The associations were tested using a Cox proportional hazards model adjusted for multivariable.  
Model 1: adjusted for age, sex 
Model 2: adjusted for age, sex, alcohol consumption, smoking status, physical activity, and BMI.  
†Subjects stratified into four groups according to the change of metabolic syndrome status as follows: MM, patients who were in MetS in both health checkups; HM, healthy 
in first checkup but newly diagnosis as MetS in the second checkup; MH, MetS in the first exam but changed to healthy in the second checkup; and HH, healthy in both 
checkups. 
‡The components of metabolic syndrome were defined based on the AHA/NHLBI definition for Asian populations as follows: 1) waist circumference ≥85 cm in women or 
≥90 cm in men, 2) serum triglycerides ≥150 mg/dL, 3) serum high-density lipoprotein (HDL) cholesterol <50 mg/dL in women or <40 mg/dL in men, 4) systolic BP ≥130 
mmHg or diastolic BP ≥85 mmHg or drug treatment for elevated BP, and 5) fasting serum glucose ≥100 mg/dL or drug treatment for elevated blood glucose. Subjects 
stratified into four groups according to the change of relevant component of metabolic syndrome as follows: UU, metabolically unhealthy of relevant component in both 
checkups; UH, metabolically unhealthy of relevant component in the first exam but changed to healthy in the second checkup; HU, metabolically healthy of relevant 
component in the first exam but changed to unhealthy in the second checkup; and HH, metabolically healthy of relevant component in both checkups 
AF, atrial fibrillation; AHA/NHLBI, American Heart Association/National Heart, Lung, and Blood Institute; BP, blood pressure; HR, hazard ratio; HDL-C, high-density 
lipoprotein cholesterol; MetS, metabolic syndrome  
  
Table S3. AF risk according to change of MetS status and each of MetS component variation including 3rd health examination. 
 Total 
  
3rd exam status Patients, n AF cases, n  
Average 
duration 
to 3rd exam 
(years)  




  Model1 Model2 
Metabolic syndrome†     
 
HH 
Healthy (HHH) 2,516,994  15,928  1.999  1.578  1 (reference) 1 (reference) 
 MetS (HHM) 321,126  3,953  2.000  3.077  1.323(1.277-1.37) 1.251 (1.208-1.296) 
 
HM 
Healthy (HMH) 203,964  2,213  2.000  2.702  1.16(1.109-1.213) 1.092 (1.044-1.142) 
 MetS (HMM) 234,198  3,399  2.000  3.641  1.335(1.286-1.386) 1.226 (1.18-1.274) 
 
MH 
Healthy (MHH) 188,865  2,280  2.000  3.004  1.189(1.138-1.243) 1.109(1.06,1.159) 
 MetS (MHM) 143,037  2,168  2.000  3.790  1.338(1.279-1.4) 1.21 (1.155-1.267) 
 
MM 
Healthy (MMH) 117,437  1,831  2.002  3.904  1.346(1.282-1.413) 1.218 (1.159-1.28) 
 MetS (MMM) 577,419  11,191  2.001  4.897  1.448(1.412-1.485) 1.273 (1.238-1.309) 
Waist circumference‡      
 
HH 
Healthy (HHH) 2,968,293  23,114  1.999  1.942  1 (reference) 1 (reference) 
 Unhealthy (HHU) 223,322  2,369  2.001  2.652  1.159(1.111-1.209) 1.112 (1.065-1.161) 
 
HU 
Healthy (HUH) 163,299  2,301  2.001  3.035  1.171(1.118-1.226) 1.122 (1.07-1.176) 
 Unhealthy (HUU) 104,462  1,602  2.000  3.438  1.388(1.327-1.453) 1.303 (1.243-1.366) 
 
UH 
Healthy (UHH) 162,536  1,966  2.000  3.538  1.222(1.17-1.276) 1.159 (1.108-1.212) 
 Unhealthy (UHU) 149,905  2,054  2.001  3.852  1.337(1.27-1.406) 1.242 (1.177-1.31) 
 
UU 
Healthy (UUH) 107,648  1,819  2.002  4.250  1.392(1.327-1.46) 1.292 (1.228-1.359) 
 Unhealthy (UUU) 423,575  7,738  2.001  4.603  1.596(1.555-1.638) 1.436 (1.387-1.488) 
Blood pressure‡      
 
HH 
Healthy (HHH) 1,579,083  7,456  1.999  1.183  1 (reference) 1 (reference) 
 Unhealthy (HHU) 314,829  2,569  2.002  2.029  1.257(1.202-1.315) 1.208 (1.155-1.264) 
 
HU 
Healthy (HUH) 273,388  1,927  1.998  1.744  1.124(1.069-1.182) 1.082 (1.029-1.138) 
 Unhealthy (HUU) 287,788  3,042  2.000  2.628  1.311(1.256-1.368) 1.232 (1.18-1.286) 
 
UH 
Healthy (UHH) 271,919  2,062  1.999  1.882  1.197(1.14-1.257) 1.148 (1.093-1.206) 
 Unhealthy (UHU) 203,678  2,197  2.001  2.681  1.353(1.289-1.419) 1.267 (1.208-1.33) 
 
UU 
Healthy (UUH) 198,680  1,997  1.998  2.497  1.281(1.219-1.347) 1.203 (1.144-1.265) 
 Unhealthy (UUU) 1,173,675  21,713  2.000  4.650  1.618(1.573-1.664) 1.474 (1.432-1.518) 
Fasting glucose‡      
 
HH 
Healthy (HHH) 2,030,296  14,521  2.000  1.782  1 (reference) 1 (reference) 
 Unhealthy (HHU) 421,751  4,341  2.002  2.572  1.146(1.108-1.185) 1.11 (1.073-1.148) 
 
HU 
Healthy (HUH) 299,416  2,895  1.999  2.404  1.086(1.043-1.13) 1.056 (1.015-1.1) 
 Unhealthy (HUU) 264,350  3,256  2.000  3.087  1.173(1.13-1.219) 1.108 (1.066-1.151) 
 
UH 
Healthy (UHH) 306,328  3,136  1.999  2.543  1.134(1.091-1.178) 1.103 (1.061-1.146) 
 Unhealthy (UHU) 184,198  2,321  2.002  3.158  1.194(1.143-1.248) 1.133 (1.084-1.184) 
 
UU 
Healthy (UUH) 146,457  1,822  1.998  3.113  1.189(1.133-1.249) 1.134 (1.08-1.191) 
 Unhealthy (UUU) 650,244  10,671  2.000  4.156  1.2(1.17-1.231) 1.11 (1.081-1.139) 
Triglycerid‡     
 
HH 
Healthy (HHH) 1,918,375  14,430  2.000  1.886  1 (reference) 1 (reference) 
 Unhealthy (HHU) 338,739  3,782  1.998  2.785  1.186(1.144-1.229) 1.135 (1.094-1.176) 
 
HU 
Healthy (HUH) 248,601  2,502  2.002  2.503  1.095(1.05-1.143) 1.043 (1-1.089) 
 Unhealthy (HUU) 288,808  3,442  2.000  2.966  1.14(1.098-1.183) 1.063 (1.023-1.103) 
 
UH 
Healthy (UHH) 251,683  2,648  1.999  2.618  1.027(0.986-1.071) 0.965 (0.925-1.006) 
 Unhealthy (UHU) 197,378  2,334  1.999  2.941  1.11(1.062-1.159) 1.017 (0.973-1.062) 
 
UU 
Healthy (UUH) 185,943  2,114  2.002  2.827  1.041(0.994-1.089) 0.951 (0.908-0.996) 
 Unhealthy (UUU) 873,513  11,711  2.001  3.350  1.144(1.116-1.172) 1.024 (0.998-1.051) 
HDL cholesterol‡      
 HH Healthy (HHH) 2,333,926  16,901  2.000  1.804  1 (reference) 1 (reference) 
 Unhealthy (HHU) 349,510  4,361  1.997  3.132  1.252(1.211-1.295) 1.204 (1.164-1.245) 
 
HU 
Healthy (HUH) 222,248  2,254  2.002  2.543  1.1(1.052-1.149) 1.061 (1.015-1.109) 
 Unhealthy (HUU) 259,706  3,598  2.000  3.488  1.204(1.161-1.249) 1.137 (1.096-1.18) 
 
UH 
Healthy (UHH) 257,564  2,628  2.001  2.533  1.105(1.06-1.151) 1.069 (1.025-1.114) 
 Unhealthy (UHU) 157,821  2,073  1.999  3.277  1.192(1.138-1.248) 1.124 (1.073-1.177) 
 
UU 
Healthy (UUH) 141,876  1,685  2.003  2.966  1.121(1.065-1.179) 1.061 (1.009-1.117) 
 Unhealthy (UUU) 580,389  9,463  2.001  4.112  1.252(1.211-1.295) 1.16 (1.128-1.192) 
Obesity‡         
 
HH 
Healthy (HHH) 2,522,301  21,715  1.999  2.152  1 (reference) 1 (reference) 
 Unhealthy (HHU) 153,664  1,391  2.002  2.246  1.194(1.131-1.26) 1.117 (1.057-1.18) 
 
HU 
Healthy (HUH) 92,445  1,062  1.998  2.862  1.197(1.125-1.273) 1.114 (1.046-1.185) 
 Unhealthy (HUU) 154,475  1,407  1.999  2.262  1.178(1.116-1.244) 1.09 (1.031-1.152) 
 
UH 
Healthy (UHH) 113,659  1,458  2.000  3.216  1.125(1.067-1.186) 0.99 (0.936-1.047) 
 Unhealthy (UHU) 84,992  1,026  2.001  3.016  1.226(1.152-1.306) 1.07 (1.001-1.142) 
 
UU 
Healthy (UUH) 107,909  1,492  2.000  3.467  1.237(1.174-1.304) 1.075 (1.016-1.138) 
 Unhealthy (UUU) 1,073,595  13,412  2.001  3.126  1.376(1.347-1.406) 1.131 (1.09-1.174) 
* The associations were tested using a Cox proportional hazards model adjusted for multivariable.  
Model 1: adjusted for age, sex 
Model 2: adjusted for age, sex, alcohol consumption, smoking status, physical activity, and BMI. † Subjects stratified into four groups according to the change of metabolic 
syndrome status as follows: MM, patients who were in MetS in both health check-ups; HM, healthy in the first check-up but newly diagnosis as MetS in the second check-
up; MH, MetS in the first exam but changed to healthy in the second check-up; and HH, healthy in both check-ups. 
‡ The components of metabolic syndrome were defined based on the AHA/NHLBI definition for Asian populations as follows: 1) waist circumference ≥85 cm in women or 
≥90 cm in men, 2) serum triglycerides ≥150 mg/dL, 3) serum high-density lipoprotein (HDL) cholesterol <50 mg/dL in women or <40 mg/dL in men, 4) systolic BP ≥130 
mmHg or diastolic BP ≥85 mmHg or drug treatment for elevated BP, and 5) fasting serum glucose ≥100 mg/dL or drug treatment for elevated blood glucose. Subjects 
stratified into four groups according to the change of relevant component of metabolic syndrome as follows: UU, metabolically unhealthy of a relevant component in both 
check-ups; UH, metabolically unhealthy of a relevant component in the first exam but changed to healthy in the second check-up; HU, metabolically healthy of a relevant 
component in the first exam but changed to unhealthy in the second check-up; and HH, metabolically healthy of a relevant component in both check-ups 
AF, atrial fibrillation; AHA/NHLBI, American Heart Association/National Heart, Lung, and Blood Institute; BP, blood pressure; HR, hazard ratio; HDL-C, high-density 
lipoprotein cholesterol; MetS, metabolic syndrome  
Table S4. AF risk according to the number of metabolic syndrome components.  
No. of MetS components 
Total, N AF patients AF incidence 
HR (95%C.I)* 
At first visit At second visit Model1 Model2 
1 ≤ 1 ≤ 3,058,312 
27,304 
(0.9%) 
1.2804 1(ref.) 1(ref.) 
 2 675,135 
10,144 
(1.5%) 
2.15799 1.201(1.173,1.229) 1.164(1.138,1.192) 
 3 250,868 4,841 (1.9%) 2.77969 1.374(1.332,1.417) 1.316(1.275,1.357) 
 ≥ 4 73,572 1,910 (2.6%) 3.75495 1.555(1.483,1.63) 1.465(1.397,1.536) 
2 1 ≤ 585,312 8,782 (1.5%) 2.15185 1.151(1.124,1.18) 1.108(1.081,1.136) 
 2 542,136 
11,269 
(2.1%) 
2.99529 1.32(1.291,1.35) 1.246(1.218,1.275) 
 3 331,180 7,708 (2.3%) 3.36023 1.417(1.381,1.454) 1.321(1.286,1.356) 
 ≥ 4 158,186 4,945 (3.1%) 4.53596 1.657(1.606,1.709) 1.516(1.469,1.565) 
3 1 ≤ 184,728 3,498 (1.9%) 2.72008 1.255(1.212,1.301) 1.193(1.151,1.236) 
 2 285,411 6,699 (2.3%) 3.38526 1.359(1.322,1.396) 1.26(1.225,1.296) 
 3 373,107 
10,231 
(2.7%) 
3.97116 1.493(1.459,1.528) 1.371(1.338,1.405) 
 ≥ 4 272,184 8,851 (3.3%) 4.72205 1.626(1.587,1.667) 1.473(1.435,1.512) 
≥ 4 1 ≤ 45,269 1,097 (2.4%) 3.49307 1.39(1.308,1.477) 1.285(1.209,1.367) 
 2 108,156 3,222 (3.0%) 4.30935 1.526(1.471,1.584) 1.394(1.342,1.448) 
 3 218,006 7,151 (3.3%) 4.76058 1.581(1.539,1.624) 1.432(1.392,1.472) 
  ≥ 4 556,633 
21,653 
(3.9%) 
5.67899 1.717(1.685,1.75) 1.523(1.492,1.556) 
* The associations were tested using a Cox proportional hazards model adjusted for multivariable.  
Model 1: adjusted for age, sex 
Model 2: adjusted for age, sex, alcohol consumption, smoking status, physical activity, and BMI.  
AF, atrial fibrillation; HR, hazard ratio  
Table S5. AF risk according to each of metabolic syndrome component changes by age. 
  AGE  20-39 40-64 ≥65 
















    Model1 Model2 Model1 Model2 Model1 Model2 
Metabolic 
syndrome† 
                        
HH 7,481 0.54783 1 (Reference) 1 (Reference) 31,187 1.74169 1 (Reference) 1 (Reference) 18,831 8.16341 1 (Reference) 1 (Reference) 















































                
HH 7,658 0.5655 1 (Reference) 1 (Reference) 43,439 1.9653 1 (Reference) 1 (Reference) 30,749 8.1027 1 (Reference) 1 (Reference) 













































Blood pressure‡                 
HH 5,073 0.51152 1 (Reference) 1 (Reference) 19,101 1.51205 1 (Reference) 1 (Reference) 6,449 6.28945 1 (Reference) 1 (Reference) 













































Fasting glucose‡                 
HH 6,458 0.54747 1 (Reference) 1 (Reference) 30,582 1.93989 1 (Reference) 1 (Reference) 22,182 8.2747 1 (Reference) 1 (Reference) 













































Triglyceride‡                 
HH 5,626 0.5325 1 (Reference) 1 (Reference) 28,775 1.92155 1 (Reference) 1 (Reference) 22,898 8.98813 1 (Reference) 1 (Reference) 













































HDL-C‡                 
HH 7,499 0.58108 1 (Reference) 1 (Reference) 33,781 1.95646 1 (Reference) 1 (Reference) 22,778 8.76279 1 (Reference) 1 (Reference) 













































Obesity                 
HH 6,008 0.54152 1 (Reference) 1 (Reference) 36,543 1.98538 1 (Reference) 1 (Reference) 32,530 8.38039 1 (Reference) 1 (Reference) 






























 UU 3,343 0.83133 














* The associations were tested using a Cox proportional hazards model adjusted for multivariable.  
Model 1: adjusted for age, sex 
Model 2: adjusted for age, sex, alcohol consumption, smoking status, physical activity, and BMI. †Subjects stratified into four groups according to the change of metabolic 
syndrome status as follows: MM, patients who were in MetS in both health checkups; HM, healthy in first checkup but newly diagnosis as MetS in the second checkup; 
MH, MetS in the first exam but changed to healthy in the second checkup; and HH, healthy in both checkups.‡The components of metabolic syndrome were defined based 
on the AHA/NHLBI definitions for Asian populations as follows: 1) waist circumference ≥85 cm in women or ≥90 cm in men, 2) serum triglycerides ≥150 mg/dL, 3) serum 
high-density lipoprotein (HDL) cholesterol <50 mg/dL in women or <40 mg/dL in men, 4) systolic BP ≥130 mmHg or diastolic BP ≥85 mmHg or drug treatment for elevated 
BP, and 5) fasting serum glucose ≥100 mg/dL or drug treatment for elevated blood glucose. Subjects stratified into four groups according to the change of relevant component 
of metabolic syndrome as follows: UU, metabolically unhealthy of relevant component in both checkups; UH, metabolically unhealthy of relevant component in the first 
exam but changed to healthy in the second checkup; HU, metabolically healthy of relevant component in the first exam but changed to unhealthy in the second checkup; 
and HH, metabolically healthy of relevant component in both checkups. AF, atrial fibrillation; AHA/NHLBI, American Heart Association/National Heart, Lung, and Blood 
Institute; BP, blood pressure; HR, hazard ratio; HDL-C, high-density lipoprotein cholesterol; MetS, metabolic syndrome  
Figure S1. Study population stratified flow according to the change of each component of metabolic syndrome. 
 
 
 
 
